Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edding Genor Group HoldingsHKSE:06998 +0.33%15 FCF Margin % is 16.24% as of Dec. 2025, which is 28% below its 10-year median of 22.43. GuruFocus rates HKSE:06998 with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 960 Drug Manufacturers companies, Edding Genor Group Holdings ranks better than 83.23% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edding Genor Group Holdings FCF Margin % Chart
Edding Genor Group Holdings Annual Data
Trend
Dec24
Dec25
FCF Margin %
28.61
16.24
Edding Genor Group Holdings Semi-Annual Data
Dec24
Dec25
FCF Margin %
28.61
16.24
HKSE:06998 vs ZTS: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Edding Genor Group Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edding Genor Group Holdings FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Edding Genor Group Holdings's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Edding Genor Group Holdings's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edding Genor Group Holdings (HKSE:06998) has a FCF Margin % of 16.24% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Edding Genor Group Holdings and its competitors. This is 28% below median its historical median of 22.43. Over the past decade, Edding Genor Group Holdings' FCF Margin % has ranged from 16.24 to 28.61. According to the industry distribution chart, Edding Genor Group Holdings ranks #161 out of 960 companies in the Drug Manufacturers industry, placing it in the top 16.8%.
Is Edding Genor Group Holdings' FCF Margin % too high?
Edding Genor Group Holdings' current FCF Margin % of 16.24% is 28% below median its 10-year median of 22.43. Over the past 10 years, this metric has ranged from a low of 16.24 to a high of 28.61. The Drug Manufacturers industry median FCF Margin % is 2.44. Edding Genor Group Holdings' value of 16.24% is 565.6% above this industry median. Based on the distribution chart, Edding Genor Group Holdings ranks #161 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Edding Genor Group Holdings has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Edding Genor Group Holdings' FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Edding Genor Group Holdings ranks #161 out of 960 companies for FCF Margin %. This places Edding Genor Group Holdings in the top 17% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.44. Edding Genor Group Holdings' value of 16.24% is 565.6% above this benchmark. Historically, Edding Genor Group Holdings' own FCF Margin % has ranged from 16.24 to 28.61 over the past decade. While the company's 10-year median is 22.43 vs. the industry median of 2.44, Edding Genor Group Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.44, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edding Genor Group Holdings's current FCF Margin % of 16.24% is 565.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Edding Genor Group Holdings and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edding Genor Group Holdings's current FCF Margin % is 16.24%, which is 28% below median its own 10-year median of 22.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edding Genor Group Holdings stock overvalued right now?
Edding Genor Group Holdings (HKSE:06998) has a current FCF Margin % of 16.24%. The current FCF Margin % is 16.24%, which is 28% below median its 10-year median of 22.43 and 565.6% above the Drug Manufacturers industry median of 2.44. Edding Genor Group Holdings' overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Edding Genor Group Holdings (HKSE:06998), the current FCF Margin % is 16.24% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Edding Genor Group Holdings Ltd is an integrated specialty biopharmaceutical company, focusing on oncology, autoimmune diseases, cardiovascular diseases, respiratory diseases, and anti-infectives. Through the acquisition of branded drug assets from multinational pharmaceutical companies (MNCs) and licensing in development and commercialisation rights of patented drugs from international biopharmaceutical companies, it has established a portfolio of originator-branded and other drugs. The company has two reportable operating segments: Manufacturing and Distribution, which generates the maximum revenue, and Research and development. Geographically, it derives maximum revenue from the Chinese mainland, and the rest from the USA and other markets.
15GF Score
Get the complete analysis for HKSE:06998
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06998 has been successfully added to your 
